New CAR-T therapy aims to outsmart stubborn blood cancers
NCT ID NCT07539610
First seen Apr 23, 2026 · Last updated May 22, 2026 · Updated 7 times
Summary
This early-stage study tests a new type of CAR-T cell therapy (Sup19) in 9 adults with B-cell leukemia or lymphoma whose cancer either stopped responding to prior CD19-targeted treatments or has weak CD19 markers. The main goal is to check safety and find the right dose, while also seeing if the therapy can shrink tumors or lead to remission.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology, Chinese Academy of Medical Sciences & Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, 300000, China
Conditions
Explore the condition pages connected to this study.